Prostate cancer screening for men over 70 is complex, with current recommendations against routine PSA testing due to slow ...

A globally-renowned prostate cancer surgeon shares the latest advancements in the field and stresses the importance of early ...

NICE recommendation of darolutamide plus hormone therapy for metastatic prostate cancer offers around 6000 patients in ...

The National Institute for Health and Care Excellence (NICE) has recommended darolutamide in combination with androgen ...

Adding the drug enzalutamide to standard hormone therapy reduced deaths by more than 40% in men with recurrent prostate ...

GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate ...

NICE recommends Bayer’s Nubeqa® (darolutamide) plus androgen deprivation therapy as a treatment option for patients with hormone-sensitive metastatic prostate cancer Nubeqa® (darolutamide) plus ...

Combining 177 Lu-PSMA-617 with SOC produced statistically significant rPFS, reducing the risk of radiographic progression or death by 28% (HR 0.72; 95% CI, 0.58-0.90) vs SOC alone in patients with ...

Patients with metastatic hormone-sensitive prostate cancer (mHSPC) lived significantly longer without disease progression ...

When prostate cancer spreads beyond the prostate gland to other parts of the body, it becomes what medical professionals call metastatic prostate cancer. This advanced form of the disease represents a ...

CNN — (CNN) — President Joe Biden’s diagnosis of metastatic prostate cancer has understandably raised concerns and questions: How long has he had cancer, how will he be treated, and what is his ...

Sept. 18, 2025 -- About 1 in 8 men will face a prostate cancer diagnosis. Early-stage prostate cancer often has no symptoms—so how should men approach screening and advocacy? What disparities do Black ...